Cara Therapeutics, Inc. (NASDAQ:CARA) Q4 2022 Results Conference Call March 6, 2023 4:30 PM ET

Company Participants

Matt Murphy - Manager, IR

Chris Posner - CEO

Ryan Maynard - CFO

Dr. Joana Goncalves - Chief Medical Officer

Conference Call Participants

Sumant Kulkarni - Canaccord Genuity

Joseph Stringer - Needham and Company

Annabel Samimy - Stifel

David Amsellem - Piper Sandler

AJ Velasquez-Mao - Jefferies

Oren Livnat - H.C. Wainwright

Jason Gerberry - Bank of America

Oren Livnat - H.C. Wainwright

Sumant Kulkarni - Canaccord Genuity

Operator

Good afternoon. My name is Josh, and I will be your conference facilitator. I would like to welcome everyone to the Cara Therapeutics Fourth Quarter and Full Year 2022 Financial Results and Update Conference Call. [Operator Instructions]

I would now like to introduce Matt Murphy, Cara's Manager of Investor Relations. Mr. Murphy, you may begin your call.

Matt Murphy

Thank you, operator, and good afternoon.

Just after market close today, Cara issued a news release announcing the Company's results for the fourth quarter and full year of 2022. Copies of this news release and the associated SEC filing can be found in the Investors section of our website at www.caratherapeutics.com.

Before we begin, let me remind you that during the course of this conference call, we will be making certain forward-looking statements about Cara and our programs based on management's current plans and expectations. These statements are being made under the Private Securities Litigation Reform Act of 1995, and are subject to various risks and uncertainties.

Actual results may differ materially due to various factors, and Cara undertakes no obligation to update or revise these statements publicly as a result of new information or future results or developments. Investors should read the risk factors set forth in Cara's 10-K for the year ended December 31, 2022, and any subsequent reports filed with the SEC.

With that said, I'd like to turn the call over to Chris Posner, Cara's Chief Executive Officer. Chris?

Chris Posner

Thanks, Matt, and good afternoon, everyone. With me today are Ryan Maynard, our Chief Financial; and Dr. Joana Goncalves, our Chief Medical Officer.

First, I want to give a quick overview of 2022 and our significant progress executing our strategy to become the world leader in the treatment of chronic pruritus. Then, I will share the latest insights into the KORSUVA injection launch and the progress in our development progress for oral difelikefalin. Ryan will follow with a financial update. After that we will be available to take your questions.